Related Experiment Videos
Association of renal graft survival with matching at the HLA-DR locus
Insights
Matching human leukocyte antigen-DR (HLA-DR) antigens significantly improves kidney transplant success. Patients receiving matched HLA-DR grafts showed better long-term renal graft survival compared to those with no match.
Area of Science:
- Immunogenetics
- Transplantation immunology
- Nephrology
Background:
- Human Leukocyte Antigen (HLA) compatibility is crucial in organ transplantation.
- HLA-DR antigen matching is a key factor influencing graft survival.
- Previous transfusions can sensitize patients, complicating transplantation.
Purpose of the Study:
- To evaluate the impact of HLA-DR antigen matching on cadaveric renal transplant graft survival.
- To determine if HLA-DR matching provides an independent benefit to renal graft outcomes.
- To analyze graft survival rates over a four-year period based on HLA-DR match status.
Main Methods:
- Retrospective analysis of 70 cadaveric renal transplants.
- Assessment of graft survival at one, two, and four years post-transplant.
- Comparison of graft survival rates between patients with one/two HLA-DR matched antigens and those with zero HLA-DR match.
- Statistical analysis to determine significance (p < 0.05).
Main Results:
- Overall cumulative renal graft survival was 62% at one year and 60% at two and four years.
- Graft survival for one/two HLA-DR matched grafts was 74% (1 yr), 69% (2 yr), and 69% (4 yr).
- Graft survival for zero HLA-DR matched grafts was 51% (1 yr), 47% (2 yr), and 47% (4 yr).
- The difference in graft survival between matched and unmatched groups was statistically significant (p < 0.05).
Conclusions:
- HLA-DR antigen matching has a significant, independent beneficial effect on renal graft survival.
- Improved outcomes are observed even in previously transfused patients.
- HLA-DR matching should be prioritized to enhance long-term kidney transplant success.
Abstract:
The influence of HLA-DR antigen matching in 70 cadaver transplants was studied for up to four years. The overall cumulative renal graft survival at one year was 62 percent, and at two and four years it was 60 percent. The one, two, and four year cumulative graft survival for patients receiving one or two HLA-DR antigen matched grafts was 74 percent, 69 percent, and 69 percent, respectively. In contrast, the one, two, and four year cumulative graft survival for patients receiving zero HLA-DR antigen matched grafts was 51 percent, 47 percent, and 47 percent, respectively. The cumulative graft survival for patients receiving one or two HLA-DR antigen matched grafts was significantly different (p less than 0.05) than for patients receiving zero HLA-DR antigen match grafts. No significant difference in the distribution of other prognostic factors were observed between patients receiving one or two HLA-DR antigen match grafts and patients receiving zero HLA-DR antigen matched grafts. The present authors concluded that matching for HLA-DR antigens exerts an independent beneficial effect on renal graft survival in transplant patients, most of whom have been previously transfused.